The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Myeloma & selinexor in 2020
Selinexor is a first-in-class, oral selective inhibitor of nuclear export (SINE) compound. Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the use of selinexor for the treatment of multiple myeloma and provides an update on the latest data regarding the therapeutic. Highlighted are data from the BOSTON trial (NCT03110562), which investigated selinexor plus bortezomib plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with R/R multiple myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Sagar Lonial, MD, has done consultancy work for Takeda, Celgene, BMS, Janssen, GSK, Abbvie, Novartis and Janssen; and has been a member of a board of directors for TG Therapeutics.
